Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19243121 | 1.00 | NPC1 (0.45) | NPC1RAB9AP2RX7KMT2AALDH1A1 | |
| SCHEMBL20677788 | 1.00 | NPC1 (0.45) | NPC1RAB9AP2RX7KMT2AALDH1A1 | |
| SCHEMBL19243151 | 0.86 | MEN1 (0.42) | NPC1RAB9AKMT2AALDH1A1TSHR | |
| SCHEMBL19209341 | 0.80 | HPGD (0.43) | NPC1RAB9AKMT2AALDH1A1TSHR | |
| SCHEMBL19243119 | 0.80 | HPGD (0.43) | NPC1RAB9AKMT2AALDH1A1TSHR | |
| SCHEMBL19209343 | 0.80 | HPGD (0.43) | NPC1RAB9AKMT2AALDH1A1TSHR | |
| SCHEMBL20677778 | 0.75 | ELANE (0.39) | NPC1RAB9AKMT2AALDH1A1HPGD | |
| SCHEMBL19243170 | 0.75 | ELANE (0.39) | NPC1RAB9AKMT2AALDH1A1HPGD | |
| SCHEMBL20677719 | 0.73 | KDM2B (0.46) | NPC1RAB9AALDH1A1HPGDHTT | |
| SCHEMBL20677718 | 0.73 | KDM2B (0.46) | NPC1RAB9AALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | EMCURE PHARMACEUTICALS LIMITED (IN) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | IDO1, IDO2, TDO2 | NPC1 4296/4885RAB9A 3617/4885P2RX7 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.